Bioequivalence Of A Test Alprazolam Sublingual Formulation Compared To A Commercial Sublingual Formulation
Status:
Withdrawn
Trial end date:
2012-10-01
Target enrollment:
Participant gender:
Summary
This study tests the assumption that the bioavailability of alprazolam from a new sublingual
formulation is the same as that from sublingual formulation expected to be used commercially
in Brazil.
Phase:
Phase 1
Details
Lead Sponsor:
Pfizer Pfizer's Upjohn has merged with Mylan to form Viatris Inc.